Literature DB >> 31801825

Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.

Anders B Sorensen1, Inga Tuneew2, L Anders Svensson2, Egon Persson2, Henrik Østergaard2, Michael Toft Overgaard3, Ole H Olsen4, Prafull S Gandhi5.   

Abstract

Two decades of research have uncovered the mechanism by which the complex of tissue factor (TF) and the plasma serine protease factor VIIa (FVIIa) mediates the initiation of blood coagulation. Membrane-anchored TF directly interacts with substrates and induces allosteric effects in the protease domain of FVIIa. These properties are also recapitulated by the soluble ectodomain of TF (sTF). At least two interdependent allosteric activation pathways originate at the FVIIa:sTF interface are proposed to enhance FVIIa activity upon sTF binding. Here, we sought to engineer an sTF-independent FVIIa variant by stabilizing both proposed pathways, with one pathway terminating at segment 215-217 in the activation domain and the other pathway terminating at the N terminus insertion site. To stabilize segment 215-217, we replaced the flexible 170 loop of FVIIa with the more rigid 170 loop from trypsin and combined it with an L163V substitution (FVIIa-VYT). The FVIIa-VYT variant exhibited 60-fold higher amidolytic activity than FVIIa, and displayed similar FX activation and antithrombin inhibition kinetics to the FVIIa.sTF complex. The sTF-independent activity of FVIIa-VYT was partly mediated by an increase in the N terminus insertion and, as shown by X-ray crystallography, partly by Tyr-172 inserting into a cavity in the activation domain stabilizing the S1 substrate-binding pocket. The combination with L163V likely drove additional changes in a delicate hydrogen-bonding network that further stabilized S1-S3 sites. In summary, we report the first FVIIa variant that is catalytically independent of sTF and provide evidence supporting the existence of two TF-mediated allosteric activation pathways.
© 2020 Sorensen et al.

Entities:  

Keywords:  X-ray crystallography; allosteric regulation; blood clotting; coagulation factor; cofactor; inflammation; protein engineering; serine protease; tissue factor; trypsin

Mesh:

Substances:

Year:  2019        PMID: 31801825      PMCID: PMC6956519          DOI: 10.1074/jbc.RA119.009183

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  XDS.

Authors:  Wolfgang Kabsch
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-01-22

2.  Sites involved in intra- and interdomain allostery associated with the activation of factor VIIa pinpointed by hydrogen-deuterium exchange and electron transfer dissociation mass spectrometry.

Authors:  Hongjian Song; Ole H Olsen; Egon Persson; Kasper D Rand
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

3.  Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study.

Authors:  C D McCallum; B Su; P F Neuenschwander; J H Morrissey; A E Johnson
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

Review 4.  Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans.

Authors:  Robert N Pike; Ashley M Buckle; Bernard F le Bonniec; Frank C Church
Journal:  FEBS J       Date:  2005-10       Impact factor: 5.542

5.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.

Authors:  D W Banner; A D'Arcy; C Chène; F K Winkler; A Guha; W H Konigsberg; Y Nemerson; D Kirchhofer
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

Review 6.  Recombinant activated factor VII: 30 years of research and innovation.

Authors:  Ulla Hedner
Journal:  Blood Rev       Date:  2015-06       Impact factor: 8.250

7.  Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa.

Authors:  R J Petrovan; W Ruf
Journal:  J Biol Chem       Date:  2000-11-14       Impact factor: 5.157

Review 8.  Vatreptacog alfa from conception to clinical proof of concept.

Authors:  Egon Persson; Ole H Olsen; Søren E Bjørn; Mirella Ezban
Journal:  Semin Thromb Hemost       Date:  2012-02-18       Impact factor: 4.180

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  Engineering of a membrane-triggered activity switch in coagulation factor VIIa.

Authors:  Anders L Nielsen; Anders B Sorensen; Heidi L Holmberg; Prafull S Gandhi; Johan Karlsson; Jens Buchardt; Kasper Lamberth; Mads Kjelgaard-Hansen; Carsten Dan Ley; Brit B Sørensen; Wolfram Ruf; Ole H Olsen; Henrik Østergaard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

View more
  3 in total

Review 1.  Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis.

Authors:  Francesco Bernardi; Guglielmo Mariani
Journal:  Haematologica       Date:  2021-02-01       Impact factor: 9.941

2.  Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain.

Authors:  Jesper J Madsen; Ole H Olsen
Journal:  Biomolecules       Date:  2021-04-08

3.  A systematic approach for evaluating the role of surface-exposed loops in trypsin-like serine proteases applied to the 170 loop in coagulation factor VIIa.

Authors:  Anders B Sorensen; Per Jr Greisen; Jesper J Madsen; Jacob Lund; Gorm Andersen; Pernille G Wulff-Larsen; Anette A Pedersen; Prafull S Gandhi; Michael T Overgaard; Henrik Østergaard; Ole H Olsen
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.